Jennifer Doudna, PhD, described to a packed crowd her journey in discovering the application of CRISPR-Cas gene editing to humans.
Proposal is one of more than 50 outlined in ‘blueprint’ for addressing rising drug prices.
The Bausch + Lomb eye care division will keep its historic name.
Alcon, Allergan, and Bausch + Lomb petitioned the high court to hear the case.
Patent challengers had a win rate of 64 percent in cases that reached a final decision in 2017, legal advisers say.
The company also filed an NDA for Roclatan, a fixed-dose combination of Rhopressa and latanoprost.
The time of day when one reads could cause myopia, according to scientists in Australia.
Companies exhibiting drug and device candidates said routine use in the clinic is on the horizon.
Regenerative medicine and patient care were common themes throughout agenda.
The MIGS device is designed to increase aqueous humor outflow from the anterior chamber to the supraciliary space.
Nashville-based Envision has asked potential acquirers to submit final offers later this month.
Quantel Group, maker of ophthalmic laser technology, combined with Keopsys Group in October 2017.
The agency said the information will be updated a semi-annual basis.
The scientific program features 350 sessions across all ophthalmic subspecialties.
Dedicated machine packs and accessories will make up a large part of the $1.6 billion in global cataract equipment revenues in 2018.
Revenues will rise most sharply in Latin America and other developing regions due to expanding access to ophthalmic surgery.
The deal is expected to close in the first half of 2019.
Additional companies that announced deals included Avedro, NeuroVision, Wuxi Vision Pro, Second Sight, and Surface.
You are not currently logged in.
©2018 Market Scope
Lost your Password